Rocco Venezia

Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ.

Founded in 2015, Intercept Pharma UK & Ireland Ltd. is a pharmaceutical wholesaler. Part of Intercept Pharmaceuticals, Inc., the private company is based in Bristol, UK.

Founded in 2016, Intercept Pharma Ltd. is a British company that engages in the development and commercialization of novel therapeutics. Part of Intercept Pharmaceuticals, Inc., the private company is based in Bristol, UK.

Part of Intercept Pharmaceuticals, Inc., Intercept Pharma Deutschland GmbH is a German company focused on building a healthier tomorrow for patients with progressive non-viral liver diseases. The private company is based in Munich, Germany. The CEOs are Rocco Venezia, Michael Gemellaro, Willem Wouter Van Weperen. The company was founded in 2015.

Part of Intercept Pharmaceuticals, Inc., Intercept Pharma France SAS is a French company that engages in the development and commercialization of novel therapeutics. The private company is based in Paris, France. The company was founded in 2015. Patrick Charre has been the CEO of the company since 2017.

Founded in 2015, Intercept Pharma Spain SLU is a Spanish pharmaceutical company that manufactures pharmaceutical products. Part of Intercept Pharmaceuticals, Inc., the private company is based in Madrid, Spain.